DaVita Inc. (DVA)
NYSE
Price as at 1 Oct 2026, 02:38 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
DaVita Inc. trades at $174.92. We do not hold enough of the inputs to value this company with the confidence the estimate implies, so we publish no fair value for it rather than a number we would not defend.
About DaVita Inc.
DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis dialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company offers integrated care and disease management services to patients in risk-based and other integrated care arrangements; clinical research programs; physician services; and comprehensive kidney care services. Further, it engages in the transplant software business. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was incorporated in 1994 and is headquartered in Denver, Colorado.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
Super investor ownership
12 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Warren Buffett, BERKSHIRE HATHAWAY INC$6.43B · 2.1% of book
- Arrowstreet Capital, ARROWSTREET CAPITAL, LIMITED PARTNERSHIP$197.80M · 0.1% of book
- D. E. Shaw, D. E. Shaw & Co., Inc.$142.57M · 0.1% of book
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$128.13M · 0.0% of book
- Ken Griffin, CITADEL ADVISORS LLC$44.47M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Politician trades in DVA
Trades in DVA disclosed by members of Congress and executive-branch officials, latest first:
- Alan Armstrong · SenateBuy · $1,001 - $15,000 · traded 27 Mar 2026 · disclosed 21 Jul 2026
- Julie Johnson · HouseSell · $1,001 - $15,000 · traded 23 Sept 2025 · disclosed 5 Aug 2026
- Julie Johnson · HouseBuy · $1,001 - $15,000 · traded 23 Sept 2025 · disclosed 5 Aug 2026
- Gilbert Cisneros · HouseSell · $1,001 - $15,000 · traded 14 Mar 2019 · disclosed 16 Apr 2019
- Dean Phillips · HouseBuy · $1,001 - $15,000 · traded 4 Feb 2019 · disclosed 21 Mar 2019
A disclosure reports a value band, not an amount, and is due up to 45 days after the trade; some arrive later. Every filer we track, each with their own page, is on the Congress trading tracker.
Common questions
Which funds own DVA?
12 of the institutions we track reported a position in DVA in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its DVA data?
Fundamentals for DVA come from company filings and exchange data, as listed on NYSE; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 1 Oct 2026, 02:38 UTC and is delayed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for DVA, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.